Cancer Genetics Inc

Cancer Genetics — Q2 2017 Earnings Presentation

22 slides from Cancer Genetics's earnings presentation, Aug 14, 2017

  1. Slide 1: Q2 2017 Earnings Report & Company Updates

    Q2 2017 Earnings Report & Company Updates Monday – August 14, 2017 | 05:00pm Eastern | CEO: Panna Sharma webcast link: http://public.viavid.com/index.php?id=125895

  2. Slide 2: Forward-Looking Statements

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growt

  3. Slide 3: Everything we do is focused on one key idea

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call EVERYTHING WE DO IS FOCUSED ON 1 KEY IDEA… .. …DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN PRECISION MEDICINE FOR ONCOLOGY DIAGNOSTICS.

  4. Slide 4: Revenue & Growth Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Revenue & Growth Highlights (numbers in $ millions) $6.6M $10.2M $18.0M $27.0M 2013 2014 2015 2016 4-Year CAGR 42% FULL YEAR REVENUE $1.5M $4.2M $7.0M $6.6M Q2 2014 Q2 2015 Q2 2016 Q2 2017 4-Year CAGR 45% 2ND QUARTER REVENUE $2.9M $8.6M $1

  5. Slide 5: Revenue & Operating Expenses

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call $4.0 $5.5 $6.1 $7.0 $6.8 $7.2 $7.0 $6.6 $6.5 $7.9 $7.1 $6.7 $6.3 $6.5 $5.6 $5.7 Q3'15 Q4'15 Q1'16 Q2'16 Q3'16 Q4'16 Q1'17 Q2'17 Revenue Operating Expenses REVENUE & OPERATING EXPENSES Amounts in $ millions Driving Operational Efficiency an

  6. Slide 6: Revenues By Market Category

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Revenues By Market Category BIOPHARMA SERVICES  CGI is now supporting over 170 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 39 for immuno-oncology indications $3.3M CLINICAL SERVICES  20% increase in cl

  7. Slide 7: Q2 2017 Financial Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Q2 2017 Financial Highlights  Q2 2017 revenues were $6.6 million, a 6% decrease over Q2 2016 revenues of $7.0 million.  Revenue from Biopharma Services decreased 21%; Clinical Services increased by 20%; and Discovery Services grew 10% in

  8. Slide 8: Additional Q2 2017 Biopharma Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Additional Q2 2017 Biopharma Highlights  Working with 9 out of the 10 top biopharma companies.  Revenue from biopharma partners and customers decreased by 21% to $3.3 million in Q2 2017 as compared to $4.2 million during Q2 2016 due to d

  9. Slide 9: Q2 2017 Clinical & Discovery Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Q2 2017 Clinical & Discovery Highlights  For the second quarter of 2017, clinical services revenue increased 20% over the same period in 2016, from $2.5 million to $3.0 million.  Clinical test volume grew 13% from 7,100 tests to 8,009 te

  10. Slide 10: Income Statement Items

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Income Statement Items ($ in Thousands) Q2 2016 Q2 2017 1H 2016 1H 2017 Revenue $7,000 $6,604 $13,069 $13,570 Gross Profit $2,716 $2,570 $4,681 $5,327 Gross Margin (%) 39% 39% 36% 39% Research & Development (R&D) $1,680 $989 $3,212 $2,099

  11. Slide 11: Q2 2017 Biopharma Highlights: Strong Year over Year Progress

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Q2 2017 Biopharma Highlights: Strong Year over Year Progress & Significant Quarterly Progress Biopharma bookings to billing ratio of 2.2 on $7.1M of Q2 2017 bookings (highest on record at CGI) 1.6 1.2 2.2 0 0.5 1 1.5 2 2.5 Q2 2016 Q1 2017

  12. Slide 12: Actively Engaged in the Expanding Liquid Biopsy Space

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Actively Engaged in the Expanding Liquid Biopsy Space Launched CGI’s first breakthrough NGS-based liquid biopsy test, Liquid::Lung-cfDNA™  Provides comprehensive coverage of 11 critical genes and 150+ hotspots related to lung cancer  Sup

  13. Slide 13: 2017 Goals

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call 2017 Goals o Multiple Myeloma NGS Panel [Mayo] o Further Expansion in Asia-Pacific o Develop Genetic Counselor Network o Expand Hereditary Service Offering o Liquid Biopsy for Kidney Cancer o Bioinformatics Center of Excellence in India o

  14. Slide 14: WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHE…

    WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 RALEIGH, NC LOS ANGELES, CA 1640 Marengo Street Fourth Floor Los Angeles, CA 90

  15. Slide 15: vivoPharm Acquisition

    CANCER GENETICS INCORPORATED Empowering Personalized Cancer Treatment vivoPharm Acquisition

  16. Slide 16: Expanding The Oncology Value Chain & CGI's Addressable Market

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Expanding The Oncology Value Chain & CGI’s Addressable Market DISCOVERY PRECLINICAL STUDIES CLINICAL TRIALS MARKET ENTRY PATIENT MONITORING  Target Selection and Validation  Lead Finding and Optimization  Pre-IND Package  Vivo Models 

  17. Slide 17: Why Australia?

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Why Australia?  Cost Efficiency  Attractive R&D tax incentives.  28% cheaper than U.S before tax incentives.  60% cheaper than US after tax incentives.  Speed  Flexible clinical trial process without compromising quality.  Quality 

  18. Slide 18: vivoPharm's Core Capabilities in a High-Growth CRO Market

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call $30.5B $46.8B $4.9B $10.2B 0 10 20 30 40 50 60 2015 2020 ROW Asia-Pacific (including Australia) $35.4B vivoPharm’s Core Capabilities in a High-Growth CRO Market Environment vivoPharm’s capabilities and portfolio are uniquely positioned to

  19. Slide 19: Expanding CGI's Geographic Footprint & Diversifying Our Customer Base

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Expanding CGI’s Geographic Footprint & Diversifying Our Customer Base 61% 24% 15% Asia-Pacific (including Australia) Europe USA  Three Global Locations:  Melbourne, Vic, Australia  Munich, Germany  Hershey, PA, United States  Over 80%

  20. Slide 20: vivoPharm is an Established Leader in Discovery & Preclinical Services

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call vivoPharm is an Established Leader in Discovery & Preclinical Services World Fair’s studies have been utilized to support over 200 IND submissions to date across a wide range of therapeutic indications  vivoPharm has over a decade of expe

  21. Slide 21: Transaction Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Transaction Highlights  The total purchase price is $12 million, with proceeds to be 90% CGIX stock, and 10% cash, supported by a $16 million equity raise.  The vivoPharm team is led by Dr. Ralf Brandt and Dr. Glenn Smits, who bring to C

  22. Slide 22: Summary

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2017 Earnings Call Summary  The acquisition strengthens CGI’s “Bench-to-Bedside” capabilities and bolsters growth with a global customer base of biopharma partners.  The acquisition expands CGI’s discovery and early development revenue base with highly com

Cancer Genetics — Q2 2017 Earnings Presentation on 6ix